Your practical Wegovy user guide: myths corrected, facts confirmed

The biggest myth: Wegovy and Ozempic are the same thing

They contain the same molecule (semaglutide) but they are not interchangeable. Ozempic is licensed in the UK specifically for type 2 diabetes. Wegovy is licensed for weight management. The doses differ, the licensed populations differ, and the regulatory approvals are separate. Presenting Ozempic as a weight-loss option is factually wrong, and a prescriber who issues it for that purpose is acting outside the product's licence.

There is also a newer form to be aware of. The MHRA approved a daily oral Wegovy tablet in June 2026 (the first oral GLP-1 medicine licensed in the UK for weight management) which follows a completely different dosing ladder (1.5mg up to 25mg, taken each morning on an empty stomach). If you have seen references to "Wegovy tablets" or "oral semaglutide for weight loss", that is what they mean. It is not the same product as the weekly injection, though it contains the same active ingredient. You can read about semaglutide in its various licensed forms if you want a fuller comparison before speaking to a prescriber.

Getting this right matters because people sometimes source what they believe is Wegovy from sellers who cannot legally supply it, or who supply counterfeit versions. The MHRA has warned repeatedly about fake pens sold online and has seized large volumes of illegally traded weight-loss medicines. Any legitimate supply requires a valid UK prescription following a clinical assessment.

How the dose schedule actually works (and why starting low is not failing

A question our prescribers hear most weeks: "I'm on 0.25mg and I haven't lost much weight yet) is something wrong?" Nothing is wrong. The starting dose exists to let your body adjust to the medicine, not to drive weight loss. Nausea and digestive discomfort are much easier to manage when the dose climbs gradually, and rushing that process typically makes side effects worse without improving outcomes.

The standard titration pathway runs 0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, reaching 2.4mg as maintenance, each step roughly four weeks apart, guided by the prescriber's clinical judgment. The MHRA also approved a 7.2mg maintenance dose in early 2026, initially available as multiple pens per week and then as a dedicated single-dose pen from April 2026. Whether a higher dose is appropriate for any individual is a clinical decision, not a personal preference. Specific dose availability at any given time is confirmed at consultation rather than assumed in advance.

For practical week-to-week use: Wegovy is injected once weekly into the abdomen, thigh, or upper arm, rotating the site each time. The pen is stored in the fridge (many people keep it in the fridge door, next to things they reach for every morning) and has a limited window for use at room temperature that is set out precisely in the Patient Information Leaflet. Always follow that leaflet rather than informal guidance, including this page's.

The Wegovy dosing guide covers the titration steps in more detail if you are trying to understand where you are in the schedule.

Side effects: what is normal, what needs attention

The most common side effects are gastrointestinal: nausea, loose stools or constipation, indigestion, reflux, and sometimes burping or fatigue. These tend to peak in the first days after starting the medicine or after a dose increase, then settle. Staying well hydrated and eating smaller portions (both of which often happen naturally as appetite reduces) helps most people through the early weeks.

A smaller number of people experience side effects that go beyond mild discomfort. Severe, persistent stomach pain that radiates toward the back, with or without vomiting, may indicate acute pancreatitis. The MHRA issued a Drug Safety Update in January 2026 specifically highlighting this risk for GLP-1 medicines: if you develop those symptoms, stop the medicine and seek urgent medical help. Gallbladder problems, signs of dehydration (dark urine, dizziness, reduced urination), and allergic reactions are also reasons to contact a healthcare professional promptly rather than waiting for your next review.

Wegovy is not recommended during pregnancy, while breastfeeding, or when trying to conceive. It is not licensed for use in people under 18. Anyone with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use semaglutide, these are standard exclusions your prescriber checks during assessment.

For women on oral contraceptives starting tirzepatide (a related but different medicine), there is specific guidance on adding a non-oral method during the early weeks of treatment; the equivalent interaction evidence for semaglutide differs, so discuss your contraception directly with your prescriber. More on this is covered on the page for people already using Wegovy.

What Wegovy's clinical results actually showed, and what they did not

STEP 1, a 68-week trial published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% at the 2.4mg maintenance dose, among adults with obesity and no diabetes, alongside lifestyle changes. That is a meaningful figure. It is also an average across thousands of participants: some people lost considerably more, others less, and individual results depend on adherence, diet, activity, metabolic factors, and clinical history.

NICE recommends Wegovy (TA875) for weight management through specialist services, for a maximum of two years, and only where specific BMI and comorbidity thresholds are met. On the NHS, access is through those specialist weight management pathways, which currently carry significant waiting lists in many areas. Private treatment through a regulated online pharmacy is a separate route for people who do not meet NHS criteria or prefer not to wait, though the clinical standards are identical. A plain breakdown of what Wegovy costs privately sets out what a legitimate price should include, which is more than just the pen.

What Wegovy does not do is work independently of everything else. The licence is for use alongside a reduced-calorie diet and increased physical activity. Most people find those changes easier to sustain because appetite falls noticeably, but the medicine works with behavioural changes, not instead of them. If you are weighing up your options, our guide to Wegovy covers how the treatment works in practice, and reading through what people using semaglutide have reported about their experience may also help you think through what fits your circumstances before you speak to a prescriber.